Version 2 2024-12-09, 17:33Version 2 2024-12-09, 17:33
Version 1 2024-12-06, 14:37Version 1 2024-12-06, 14:37
journal contribution
posted on 2024-12-09, 17:33authored byXiaokai Chen, Xiaodong Zhang, Yang Liu, Yun Chen, Yanli Zhao
Optogenetics, a revolutionary technique utilizing light-sensitive
proteins to control cellular functions with high spatiotemporal precision,
presents a promising avenue for disease treatment; however, its application
in cancer therapy remains constrained by limited research. Herein,
we introduce a pioneering strategy for remote-controlled optogenetic
cancer therapy, synergistically merging optogenetics with ion therapy,
which incorporates ion self-supply, in situ ion channel construction,
and near-infrared (NIR) light-activated ion therapy, facilitating
remote and noninvasive manipulation of cellular activities in deep
tissues and living animals. We report the facile synthesis of water-dispersible
upconversion nanoparticle (UCNP)–metal–organic framework
(MOF) nanohybrids capable of effectively delivering plasmid DNA to
cancer cells, thereby enabling the in situ expression of photoactivatable
cation channels. The pH-responsive MOF components serve as a reservoir
for metal cations, which are released in the acidic microenvironment
of tumors, while the UCNP components function as remote-controlled
transducers, converting near-infrared (NIR) light into visible light
to activate the cation channels and allowing the cancer influx of
released metal cations for ion therapy. The proposed remote-controlled
cancer optogenetic therapy demonstrates its effectiveness across multiple
tumor models, including subcutaneous colon tumors, subcutaneous breast
tumors, and orthotopic breast tumors. This study represents a significant
step toward the realization of optogenetics in clinics, with substantial
potential for advancing cancer therapy.